Chapter
stringclasses 62
values | Section
stringclasses 571
values | Subsection
stringclasses 845
values | Subsubsection
stringclasses 240
values | Text
stringlengths 1
4.01k
|
|---|---|---|---|---|
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | treatment issues, 1103–1107 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | Z |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | Zoledronic acid |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | aromatase inhibitors, 757 bone metastases and, 1068 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | characteristics of, 685–687, 688t, 689 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | osteoporosis, 719, 1068 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | ovarian ablation, 630, 631 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | Zuska’s disease, 85 |